New Delhi: In a significant verdict redefining the boundaries of trademark protection in the pharmaceutical sector, the Delhi High Court has ruled that English alphabets and common phrases denoting completeness—such as "A to Z"—cannot be monopolized by a single entity. The Court vacated an earlier ex-parte injunction granted to pharma giant Alkem Laboratories, thereby allowing its competitor, Prevego Healthcare, to continue marketing its multivitamin product under the brand "Multivein AZ."
The Bench, led by Justice Tejas Karia, observed that the mark "A to Z" is inherently descriptive when used for health supplements, as it suggests a comprehensive range of vitamins or benefits.
The Case: Alkem vs. Prevego
The dispute arose when Alkem Laboratories, the makers of the popular "A to Z" and "A to Z-NS" health supplements, dragged Prevego Healthcare to court. Alkem alleged that Prevego’s use of the suffix "AZ" in their product "Multivein AZ" infringed upon their established trademark and confused consumers.
Alkem argued that they had been using the "A to Z" mark since 1998 and that the defendant's adoption of "AZ" was a calculated attempt to ride on their goodwill. They claimed that the visual and phonetic similarity between the marks would mislead the public.
The Court’s Observations: No Monopoly on Language
Rejecting Alkem’s contentions, Justice Karia applied the "anti-dissection rule," holding that trademarks must be compared as a whole rather than by isolating specific elements. The Court noted that the prefix "Multivein" in the defendant's mark was the dominant feature, sufficient to distinguish it from Alkem's product.
Crucially, the Court addressed the claim over the letters themselves. It held that "A to Z" is a common English phrase widely used to denote "everything" or "completeness."
"The Mark 'A TO Z' is descriptive in nature. Therefore, the Plaintiff cannot be allowed to monopolize the use of the letters 'A' and 'Z' by seeking exclusivity over the right to use the letters 'A' and 'Z'."
The Court further clarified that while Alkem might have copyright protection over the stylized artistic design of their logo, this does not translate into a monopoly over the text of the letters themselves.
Suppression of Material Facts
The judgment also heavily criticized Alkem Laboratories for "unclean hands." The Court found that Alkem had failed to disclose that its previous applications for the "A to Z" word mark in Class 5 (pharmaceuticals) had been either withdrawn, abandoned, or opposed by the Registry. This suppression of material facts became a key ground for vacating the injunction.
Why This Matters
This ruling serves as a critical check on aggressive intellectual property litigation in the pharma industry. It reinforces the principle that generic terms and common alphabets are publici juris (of public right) and cannot be fenced off by corporations to stifle competition. For the industry, it signals that adding a common suffix like "AZ" to a distinct brand name is unlikely to constitute infringement, provided the overall packaging remains distinct.